Histologic subtype urothelial cancers are rare but often aggressive. Our multidisciplinary team reviewed the available literature to date on management of these cancer, just published in @EUplatinum sciencedirect.com/science/articl…
Latest posts 5
Congratulations to my mentee @JeffreyYZhong for being selected for this BCAN honor based on his work on real world outcomes with enfortumab vedotin dose reductions! @UHhospitals @caseccc @PBarataMD @koshkin85 @PGrivasMDPhD
Also kudos to my MSTP colleague @curtperrymdphd as well
Also kudos to my MSTP colleague @curtperrymdphd as well
Congratulations to the 2026 John Quale Travel Fellowship recipients! We are proud to support the next generation of bladder cancer researchers and clinicians as they join us at the 2026 Bladder Cancer Think Tank. Your dedication to advancing bladder cancer research will help shape the future of patient care. @UofCalifornia @MSKCancerCenter @WeillCornell @Yale @theNCI @UW @MoffittNews @UHhospitalsView quoted post on X
My colleague @PBarataMD @UHhospitals presenting 177Lu-rosopatamab post-ARPI #ASCO26
☢️ Radiotherapeutic ADC
➕ Combination w physician choice (ARPI, chemo), few pts progressed
👅 Low salivary gland, renal exposure
🩸 Tolerable with most common toxicities hematologic, fatigue
☢️ Radiotherapeutic ADC
➕ Combination w physician choice (ARPI, chemo), few pts progressed
👅 Low salivary gland, renal exposure
🩸 Tolerable with most common toxicities hematologic, fatigue
Excellent discussion of pooled analysis of probiotic CBM-588 w ICI in mRCC #ASCO26
🦠 Probiotics improve clinical outcomes
🧬 SIG-1 genotype more likely to respond, S score predict benefit w Ipi/Nivo
🔜 Important to support Biofront study @SWOG led by @PBarataMD @UHhospitals
🦠 Probiotics improve clinical outcomes
🧬 SIG-1 genotype more likely to respond, S score predict benefit w Ipi/Nivo
🔜 Important to support Biofront study @SWOG led by @PBarataMD @UHhospitals
Bulumtatug fuvedotin + toripalimab in aUC #ASCO26
🇨🇳 Next gen Nectin-4 targeting ADC w MMAE payload
🥊 83% ORR, 89% DCR
⚡️ Similar toxicity to other ADCs
🔜 Future development in China
🇨🇳 Next gen Nectin-4 targeting ADC w MMAE payload
🥊 83% ORR, 89% DCR
⚡️ Similar toxicity to other ADCs
🔜 Future development in China